comparemela.com


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
VA San Diego Healthcare System Joins the Phase II Trial of LSALT Peptide for the Treatment of ...
Arch BiopartnersDecember 10, 2020 GMT
TORONTO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Veterans Affairs San Diego Healthcare System (VASDHS) has started recruiting patients for the Phase II trial of its lead drug LSALT peptide, targeting the prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19.

Related Keywords

China ,Florida ,United States ,California ,Louisiana ,Canada ,Toronto ,Ontario ,Turkey ,Canadian ,Mark Hepokoski ,Arch Biopartners Inc ,Veterans Affairs San Diego Healthcare System ,Arch Biopartners ,Chief Science ,சீனா ,புளோரிடா ,ஒன்றுபட்டது மாநிலங்களில் ,கலிஃபோர்னியா ,லூசியானா ,கனடா ,டொராண்டோ ,ஆஂடேரியொ ,வான்கோழி ,கனடியன் ,வீரர்கள் வாழ்க்கைத்தொழில்கள் சான் டியாகோ சுகாதாரம் அமைப்பு ,தலைமை அறிவியல் ,

© 2024 Vimarsana

comparemela.com © 2020. All Rights Reserved.